

Updates to Recommendations for Vaccines in People with HIV

Shireesha Dhanireddy, MD
University of Washington

Last Updated: 1 December 2021

Disclosures

No conflicts of interest to disclose


Question:

- A 40 year old man with HIV (CD4 count 450, HIV RNA UD, on DTG + F/TAF) presents for routine visit. He would like to know which vaccines are needed. He notes that he had an episode of shingles at the time of diagnosis of HIV 10 years ago.


Which of the following is true regarding zoster vaccine?

1. He does not need zoster vaccine as he has had zoster
2. You may give live zoster vaccine today
3. You may give recombinant zoster vaccine today and again in 2 months
4. He is not eligible for zoster vaccine as he is under 50

Recombinant Zoster Vaccine (RZV, Shingrix[®])



Efficacy of RZV (Shingrix®) for Prevention of 1st Episode Zoster in Immunocompetent Patients ≥ 50




Source: Lal H, et al. N Eng J Med. 2015

Figure modified from David Spach




Are people with HIV at increased risk for herpes zoster (HZ)?

Incidence of HZ
higher in people
with HIV




Data in IC Hosts Often After Approval and Initial Recommendations

Efficacy of RZV in Preventing Incident Herpes Zoster in Patients Who Had Undergone HSCT



Source: Bastidas et al. JAMA 2019.

October 2021 - CDC ACIP voted to recommended RZV to adults ≥ 19 who are or will be immunosuppressed due to disease or therapy

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 count		Asplenia, complement deficiencies	End-stage renal disease; or on hemodialysis	Heart or lung disease, alcoholism ¹	Chronic liver disease	Diabetes	Health care personnel ²	Men who have sex with men		
			<200 ³	$\geq 200^3$									
RZV ⓘ												2 doses at age ≥ 50 yrs	
													
RZV ⓘ												2 doses at age ≥ 19 yrs	2 doses at age ≥ 50 yrs

Other questions

- What is the optimal timing?
 - Consider waiting until on ART and suppressed
 - RZV can be given to people on antivirals (i.e. acyclovir)
 - Wait until after no active zoster lesions to give vaccine
- Should I check varicella titers first?
 - RZV is not indicated for primary varicella infection
 - Sensitivity and specificity of IgG assays can vary
 - Safety data regarding use of RZV in VZV naïve persons is limited

Question:

- A 40 year old man with HIV (CD4 count 450, HIV RNA UD, on DTG + F/TAF) presents for routine visit. He has never received a pneumococcal vaccine.

Which of the following is true regarding pneumococcal vaccination?

1. He should receive PCV20 today followed by PPSV23 in 8 weeks and again in 5 years
2. He should receive PCV20 today and does not need PPSV23
3. He should receive PCV13 today followed by PPSV23 in 8 weeks and again in 5 years
4. He should receive PCV15 today followed by PPSV23 in 8 weeks

Pneumococcal Vaccination in PWH

- CDC ACIP recommended PCV20 or PCV15 to all individuals ≥ 65 years who have not received PCV before or if unknown
- For PWH, individuals with asplenia and others at increased risk, give PCV20 or PCV15 at age 19-64
 - If PCV15 given, then give PPSV23

Why the change?

- Potential waning of immunity later for those 65+
- Cost-saving in cost-effectiveness analyses
- New recommendations provide opportunity for higher PCV coverage – to prevent more disease and address equity concerns
- Simplify recommendations

Differences between coverage of serotypes


Serotypes Contained in Current and New Pneumococcal Vaccines

	1	3	4	5	6A	6B	7 F	9V	14	18 C	19 A	19 F	23 F	22 F	33 F	8	10 A	11 A	12 F	15 B	2	9N	17 F	20	
PCV13	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow												
PCV15	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Green	Green										
PCV20	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Green	Green	Blue	Blue	Blue	Blue	Blue	Blue				
PPSV23	Yellow	Yellow	Yellow	Yellow	White	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Yellow	Green	Green	Blue	Blue	Blue	Blue	Blue	Blue	Orange	Orange	Orange	Orange

- PCV15 non-PCV13: includes serotypes 22F and 33F
- PCV20 non-PCV13: includes serotypes 22F, 33F, 8, 10A, 11A, 12F, and 15B
- PPSV23 non-PCV20: includes serotypes 2, 9N, 17F, and 20

Invasive Pneumococcal Disease in IC Hosts

Proportion of IPD by Serotype Groups in Adults aged 19–64 Years with Risk-based Indications



ABCs 2017–2018

PCV15 non-PCV13 serotypes: 22F, 33F
PCV20 non-PCV15 serotypes: 8, 10A, 11A, 12F, 15B/C
PPSV23 non-PCV20 serotype: 2, 9N, 17F, 20

CMC

CMC: chronic medical conditions
IC: immunocompromising conditions

Final Thoughts

- Official recommendations will be issued in MMWR, likely January 2022 and will be published in new immunization schedules February 2022 as well
- Zoster vaccine for all adult PWH!
- Easier to remember pneumococcal vaccination schedule (yay!)

Questions?

Acknowledgment

The Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$2,886,754 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.

